A Randomized, Safety-assessor Blinded Trial Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in Adult Subjects Scheduled for Surgery Requiring Profound Neuromuscular Blockade

Trial Profile

A Randomized, Safety-assessor Blinded Trial Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in Adult Subjects Scheduled for Surgery Requiring Profound Neuromuscular Blockade

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Sugammadex (Primary)
  • Indications Neuromuscular blockade
  • Focus Registrational; Therapeutic Use
  • Acronyms Sunlight
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 03 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top